Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8+ T cell dysfunction and maintain memory phenotype
- 1 November 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (29)
- https://doi.org/10.1126/sciimmunol.aat7061
Abstract
Most patients with cancer do not develop durable antitumor responses after programmed cell death protein 1 (PD-1) or programmed cell death ligand 1(PD-L1) checkpoint inhibition monotherapy because of an ephemeral reversal of T cell dysfunction and failure to promote long-lasting immunological T cell memory. Activating costimulatory pathways to induce stronger T cell activation may improve the efficacy of checkpoint inhibition and lead to durable antitumor responses. We performed single-cell RNA sequencing of more than 2000 tumor-infiltrating CD8(+) T cells in mice receiving both PD-1 and GITR (glucocorticoid-induced tumor necrosis factor receptor-related protein) antibodies and found that this combination synergistically enhanced the effector function of expanded CD8(+) T cells by restoring the balance of key homeostatic regulators CD226 and T cell immunoreceptor with Ig and ITIM domains (TIGIT), leading to a robust survival benefit. Combination therapy decreased CD8(+) T cell dysfunction and induced a highly proliferative precursor effector memory T cell phenotype in a CD226-dependent manner. PD-1 inhibition rescued CD226 activity by preventing PD-1-Src homology region 2 (SHP2) dephosphophorylation of the CD226 intracellular domain, whereas GITR agonism decreased TIGIT expression. Unmasking the molecular pathways driving durable antitumor responses will be essential to the development of rational approaches to optimizing cancer immunotherapy.This publication has 50 references indexed in Scilit:
- Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery, 2018
- Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.Journal of Clinical Oncology, 2017
- Cancer immunotherapies targeting the PD-1 signaling pathwayJournal of Biomedical Science, 2017
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug DiscoveryCancer Immunology Research, 2017
- Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockadeScience, 2016
- The epigenetic landscape of T cell exhaustionScience, 2016
- Rationale for anti-GITR cancer immunotherapyEuropean Journal of Cancer, 2016
- Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor ModelCancer Immunology Research, 2015
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugsJournal of Translational Medicine, 2014
- Advances in targeting cell surface signalling molecules for immune modulationNature Reviews Drug Discovery, 2013